Navigation Links
Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
Date:12/16/2008

NEW YORK, LONDON and HAMILTON, Bermuda, Dec. 16 /PRNewswire/ --Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") announced today that the databases have been locked and preliminary analyses completed on the two double-blinded studies of XERECEPT(R) (corticorelin acetate), as a treatment for peritumoral brain edema, as well as an initial database lock on the open-label study of XERECEPT's long-term safety and efficacy.

The results of these studies are the subject of several abstract submissions for the American Society of Clinical Oncology (ASCO) annual meeting in May 2009, as well as the American Association of Cancer Research annual meeting (AACR) in April 2009. In conformance with the requirements of both ASCO and AACR, XERECEPT(R) datawill be published only after presentation at these meetings.

Celtic Pharma has also retained a top-tier investment bank to serve as its financial advisor in the planned sale in 2009 of Neutron Holdings Limited and its geographical subsidiaries who are the owners of the worldwide commercial rights to XERECEPT(R).

"We believe that the trial data we now have in hand indicate the efficacy and long term safety of Xerecept as a treatment for cerebral edema associated with primary and metastatic brain tumors, permitting substantial reductions or elimination of cortico-steroid dosing in this patient population, and that Xerecept has the potential to become part of the generally accepted standard of care for these patients." said Stephen Evans-Freke, Managing General Partner of Celtic Pharma. "We believe we have built substantial value in Xerecept(R) and we look forward to achieving superior returns for our investors through the sale of this important program in 2009." said John Mayo, co-Managing General Partner of Celtic Pharma.

About Celtic Pharmaceutical Holdings L.P.

Celtic Pharmaceutical
'/>"/>

SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
3. Pharmasset Reports Fiscal Year End 2008 Financial Results
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
6. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
7. Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
8. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
9. Mission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin
10. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
11. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 The role of the ... but one thing hasn,t changed: face-to-face meetings are seen ... with Key Opinion Leaders. Yet at the ... valuable type of interaction, field medical teams within the ... interactions. This is just one of the challenges addressed ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... published in the Proceedings of the National ... showed when ibrutinib (IMBRUVICA ® ) was combined ... of tumor growth was enhanced suggesting a greater ... cancers and solid tumors with the combination. IMBRUVICA ...
(Date:2/27/2015)... 2015 - ... di monitoraggio dell,infarto congestizio (CHF - Congestive Heart ...     Vectorious Medical Technologies, ... per il monitoraggio cardiaco destinato a pazienti affetti ... aver concluso una raccolta di finanziamenti per 5 ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... Nov. 2, 2010 Hanger Orthopedic Group, Inc. (NYSE: ... York City time, on Monday, November 1, 2010 (the "Early ... Notes due 2014 (the "Notes") have been validly tendered and ... tender offer (the "Offer") for any and all of its ...
... and BUDAPEST, Hungary, November 2, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces Early Tender Results of Offer to Purchase Outstanding 10-1/4% Senior Notes Due 2014 2Hanger Orthopedic Group, Inc. Announces Early Tender Results of Offer to Purchase Outstanding 10-1/4% Senior Notes Due 2014 3National Institute of Advanced Industrial Science and Technology (AIST) Adopts ChemAxon JChem Base for Japanese Consortium for Glycobiology and Glycotechnology Database (JCGGDB) 2National Institute of Advanced Industrial Science and Technology (AIST) Adopts ChemAxon JChem Base for Japanese Consortium for Glycobiology and Glycotechnology Database (JCGGDB) 3National Institute of Advanced Industrial Science and Technology (AIST) Adopts ChemAxon JChem Base for Japanese Consortium for Glycobiology and Glycotechnology Database (JCGGDB) 4National Institute of Advanced Industrial Science and Technology (AIST) Adopts ChemAxon JChem Base for Japanese Consortium for Glycobiology and Glycotechnology Database (JCGGDB) 5National Institute of Advanced Industrial Science and Technology (AIST) Adopts ChemAxon JChem Base for Japanese Consortium for Glycobiology and Glycotechnology Database (JCGGDB) 6National Institute of Advanced Industrial Science and Technology (AIST) Adopts ChemAxon JChem Base for Japanese Consortium for Glycobiology and Glycotechnology Database (JCGGDB) 7National Institute of Advanced Industrial Science and Technology (AIST) Adopts ChemAxon JChem Base for Japanese Consortium for Glycobiology and Glycotechnology Database (JCGGDB) 8National Institute of Advanced Industrial Science and Technology (AIST) Adopts ChemAxon JChem Base for Japanese Consortium for Glycobiology and Glycotechnology Database (JCGGDB) 9
(Date:2/28/2015)... March—also known as National Brain Injury ... and others that suspected head injuries, especially concussions, ... , Concussions are a form of traumatic brain ... There are 1.6-3.8 million sports-related concussions per year. ... is a brain injury. Many athletes suffer knee ...
(Date:2/28/2015)... 28, 2015 Vancouver personal injury lawyers at ... are affected by time limits. They stated that in many ... claim or even nullify it. Many a time, delays in ... client’s rights under BC law. As a result, experts at ... accidents should consult a personal injury lawyer in order to ...
(Date:2/28/2015)... 28, 2015 A study out of ... gene therapy procedure for the treatment of a hereditary ... Authored by Dr. Robert MacLaren, professor of ... the Lancet Medical Journal on January 16, 2014 , ... rare genetic disorder that mostly affects men and leads ...
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation ... International Symposium on Malignant Mesothelioma on Monday, March 2. ... Regency Bethesda in Bethesda, Maryland. The following award recipients ... to the mission to cure mesothelioma. , The Klaus ... to Miriam Ratner. Miriam runs the Meso Foundation’s monthly ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 ... of outsourced sales, marketing and supply chain management ... BIOTA Botanicals, is bringing its award winning solutions ... BIOTA Botanicals’ products are specifically created to combat ... experts, BIOTA is committed to marrying science with ...
Breaking Medicine News(10 mins):Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... ... it,s new shop in Beverly Hills, featuring old style barbering, straight razor shaves, in a ... ... today the official opening of its Beverly Hills store located at 9635 Brighton Way, Beverly ...
... ... Everyone,The largest and most exciting health fair ever to be held in Clark County is being ... Kids, sports fans, senior citizens, gun owners, dog lovers, teenage drivers, moms, and dads will all ... ...
... ... ... , ... , , , , ...
... ... the stem cell revolution, is on a 10 city speaking/book tour including Spokane. He will ... ... the stem cell phenomenon made a science book an overnight Amazon Best Seller and catapulted ...
... ... ... ... , ...
... ... ... ... ...
Cached Medicine News:Health News:The Classic Shave Company Announces the Opening of Beverly Hills Shop 2Health News:Vancouver, Washington -- Free Family Fun at Health Fair 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire an Approximately 260,500 Square Foot Medical Office Portfolio in Indiana 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire an Approximately 260,500 Square Foot Medical Office Portfolio in Indiana 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire an Approximately 260,500 Square Foot Medical Office Portfolio in Indiana 4Health News:Health: Surprise Best Seller is Stem Cell Book – Author in Spokane - 10 City Tour 2Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 2Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 3Health News:Medicare Advantage Members May Make Changes During Open Enrollment 2Health News:Medicare Advantage Members May Make Changes During Open Enrollment 3
Flat handle....
Thin and smooth jaws, cross action....
Angled shafts, smooth jaws, polished finish....
... This direct-acting inserter grasps the thinnest ... rim, resulting in a minimum incision requirement. ... around the thicker center of the optic ... optic, resulting in delivery of an implant ...
Medicine Products: